全球核医学市场（2023-2030）：规模、份额、按产品类型（诊断（SPECT/PECT）/治疗（ALPHA发射器/BETA发射器））和应用（心脏病/神经病学/肿瘤学）预测的增长分析

全球核医学市场将从2021年的81亿美元和2022年的89亿美元增长到2030年的244亿美元，预测期内復合年增长率为13%。预计

由于强大的产品线和旨在增加获得这些技术的政府支持举措，核医学市场正在不断增长。 儘管受到 COVID-19 的影响，在基本药物生产中发挥重要作用的核反应堆仍在继续运行，并采取了严格的安全措施。 前列腺癌是一个主要问题，尤其是老年男性，最近 Pluvicto (177Lu-PSMA-617) 被美国 FDA 批准用于治疗转移性前列腺癌。 这进一步凸显了核医学的进步。

癌症和心血管疾病的发病率和患病率上升是推动核医学市场扩张的主要因素。 这些疾病往往可以通过早期发现和早期治疗来预防，而核医学发挥着重要作用。 根据世界卫生组织 (WHO) 的数据，癌症是 2020 年的首要死因，预计到 2025 年癌症病例数还会增加。 同样，心血管疾病占 2019 年全球死亡人数的大部分，预计到 2030 年将进一步增加。 核医学在这些疾病的诊断和治疗中的应用将带来显着的市场增长。 核成像技术（尤其是 PET/PET-CT）的技术进步已将其应用范围从肿瘤学扩展到心脏病学、神经学和传染病检测等领域。 人们越来越认识到早期诊断和改善疾病管理的积极影响，进一步推动市场增长，导致 PET 和 SPECT 手术数量增加。

在本报告中，我们调查了全球核医学市场，并提供了市场概况、市场各种影响因素分析、技术和创新趋势、法律和监管环境、市场规模的转变和预测、各种细分市场和地区。编制了单独的细分、竞争格局、主要参与者的概况等。

内容

执行摘要

调查方法

母公司市场分析

• 市场概况
• 市场规模
• 市场动态
  • 驱动程序
  • 机会
  • 制约因素
  • 任务

主要市场洞察

• 技术分析
• 价格分析
• 供应链分析
• 价值链分析
• 市场生态系统
• 知识产权分析
• 贸易分析
• 启动分析
• 原材料分析
• 创新矩阵
• 管道产品分析
• 宏观经济指标
• 主要投资分析
• 关键成功因素
• 争用程度

市场动态与展望

• 市场动态
  • 驱动程序
  • 机会
  • 制约因素
  • 任务
• 监管状况
• 波特的分析
• Skyquest 对未来颠覆的特殊洞察

按产品类型划分的全球核医学市场

• 市场概况
• 诊断（SPECT/PECT）
• 处理（ALPHA发射器/BETA发射器）
• 近距离放射治疗

全球核医学市场：按应用分类

• 市场概况
• 心脏病学和神经病学系
• 肿瘤
• 甲状腺
• 淋巴瘤
• 骨转移
• 内分泌肿瘤
• 其他

全球核医学市场：按地区

• 市场概况
• 北美
• 欧洲
• 亚太地区
• 拉丁美洲
• 中东和非洲

竞争格局

• 排名前 5 名的公司比较
• 主要公司的市场定位
• 各大公司的招聘策略
• 关键成功策略
• 近期市场活动
• 主要公司的市场份额

主要公司简介

• GE Healthcare
• Siemens Healthineers
• Philips Healthcare
• Curium Pharma
• Cardinal Health
• Bracco Imaging
• Eckert &Ziegler
• Lantheus Medical Imaging
• Jubilant Life Sciences
• Nordion Inc.
• IBA Molecular
• Advanced Accelerator Applications (AAA)
• Progenics Pharmaceuticals
• Norgine BV
• FUJIFILM Holdings Corporation
• Bayer Healthcare
• Theragnostics
• RadioMedix Inc.
• Ion Beam Applications SA (IBA)
• Novartis AG

Global Nuclear Medicine Market size was valued at USD 8.1 billion in 2021 and is poised to grow from USD 8.9 billion in 2022 to USD 24.4 billion by 2030, growing at a CAGR of 13% in the forecast period (2023-2030).

Nuclear medicine is a specialized field within radiology that utilizes small amounts of radioactive materials to examine organ structure and function. It combines various disciplines such as chemistry, physics, mathematics, computer technology, and medicine. This branch of radiology is particularly valuable in diagnosing and treating diseases at early stages, such as thyroid cancer. While standard X-rays have limitations in visualizing soft tissues, nuclear medicine imaging enables clearer visualization of organs and tissues. The market for nuclear medicine is experiencing growth due to a robust product pipeline and supportive government initiatives aimed at enhancing access to these technologies. Despite the impact of the COVID-19 pandemic, nuclear reactors, which play a critical role in producing essential medicines, have continued operations with stringent safety measures. Prostate cancer is a significant concern, with high incidence rates, particularly among older men. The recent approval of Pluvicto (177Lu-PSMA-617) by the U.S. FDA for the treatment of metastatic prostate cancer further underscores the advancements in nuclear medicine.

Segments covered in this report:

Global nuclear medicine market has been segmented based on product type, application, end use, procedure, and region. Based on product type, global nuclear medicine market are further sub-segmented into diagnostic (SPECT and PET), therapeutic (alpha emitters and beta emitters), and brachytherapy. On the basis of application, global nuclear medicine market is segmented into cardiology neurology, oncology, thyroid, lymphoma, bone metastasis, endocrine tumour, and others. According to end use, global nuclear medicine market is segmented into hospitals & clinics, diagnostic centers and others. By procedure, the market is segmented into central nervous system, endocrine, skeletal, gastrointestinal, genito-urinary, pulmonary. By region, the market is segmented into North America, Europe, Asia Pacific, Latin America, and MEA.

Driver

The increasing incidence and prevalence of cancer and cardiovascular disease are key factors driving the expansion of the nuclear medicine market. These diseases can often be prevented through early detection and treatment, where nuclear medicine plays a crucial role. According to the World Health Organization (WHO), cancer was the leading cause of death in 2020, with an expected rise in new cases worldwide by 2025. Similarly, cardiovascular disease accounted for a significant number of global deaths in 2019, with projections indicating a further increase by 2030. The utilization of nuclear medicine in diagnosing and treating these conditions positions it for significant market growth. Technological advancements in nuclear imaging modalities, particularly PET/PET-CT, have expanded its applications beyond oncology to areas like cardiology, neurology, and infection detection. The increased awareness of the positive impact of early diagnosis and improved disease management further drives market growth, resulting in a rise in PET and SPECT procedures.

Restraint

The growth of the nuclear medicine imaging market is expected to be restrained in the coming years due to the increasing adoption of alternative diagnostic options such as MRI and CT scans. These alternatives are more cost-effective compared to nuclear medicines, leading to their greater use, especially in developing nations. Moreover, reimbursement policies favor the utilization of MRI and CT scans, further hindering the market for nuclear medicine. Additionally, the high cost associated with nuclear imaging systems and procedures, along with the extensive use of CT and MRI scans annually, pose a risk to the volume of PET-CT procedures.

Key Market Trend

The market for nuclear medicine therapies is witnessing a focus on development by companies, driven by the clinical benefits of this treatment option compared to others. The demand for nuclear medicine therapies is expected to rise globally, supported by the positive outcomes observed in the treatment of cancer and other disorders. This is particularly significant in countries with a high cancer burden. For instance, Curium received FDA approval to initiate a Phase-III trial for lutetium Lu 177 PSMA I&T, a radiopharmaceutical targeting Prostate-Specific Membrane Antigen (PSMA). Many market participants are also actively developing new therapeutic products for various medical conditions, contributing to the growth of the market.

Table of Contents

Executive Summary

• Market Overview
• Wheel of Fortune

Research Methodology

• Information Procurement
• Secondary & Primary Data Sources
• Market Size Estimation
• Market Assumptions & Limitations

Parent Market Analysis

• Market Overview
• Market Size
• Market Dynamics
  • Drivers
  • Opportunities
  • Restraints
  • Challenges

Key Market Insights

• Technology Analysis
• Pricing Analysis
• Supply Chain Analysis
• Value Chain Analysis
• Ecosystem of the Market
• IP Analysis
• Trade Analysis
• Startup Analysis
• Raw Material Analysis
• Innovation Matrix
• Pipeline Product Analysis
• Macroeconomic Indicators
• Top Investment Analysis
• Key Success Factor
• Degree of Competition

Market Dynamics & Outlook

• Market Dynamics
  • Drivers
  • Opportunities
  • Restraints
  • Challenges
• Regulatory Landscape
• Porters Analysis
  • Competitive rivalry
  • Threat of Substitute Products
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers
• Skyquest Special Insights on Future Disruptions
  • Political Impact
  • Economic Impact
  • Social Impact
  • Technical Impact
  • Environmental Impact
  • Legal Impact

Global Nuclear Medicine Market by Product type

• Market Overview
• Diagnostic (SPECT AND PECT)
• Therapeutic (Alpha Emitters and Beta Emitters)
• Brachytherapy

Global Nuclear Medicine Market by Application

• Market Overview
• Cardiology Neurology
• Oncology
• Thyroid
• Lymphoma
• Bone Metastasis
• Endocrine Tumor
• OthersSegmentEnd-userSub-SegmentsHospitals & Clinics
• Diagnostic Centers and OthersSegmentProcedureSub-SegmentsCentral Nervous System
• Endocrine
• Skeletal
• Gastrointestinal
• Genito-urinary
• Pulmonary

Global Nuclear Medicine Market Size by Region

• Market Overview
• North America
  • USA
  • Canada
• Europe
  • Germany
  • Spain
  • France
  • UK
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America
  • Brazil
  • Rest of Latin America
• Middle East & Africa (MEA)
  • GCC Countries
  • South Africa
  • Rest of MEA

Competitive Landscape

• Top 5 Player Comparison
• Market Positioning of Key Players, 2021
• Strategies Adopted by Key Market Players
• Top Winning Strategies
  • By Development
  • By Company
  • By Year
• Recent Activities in the Market
• Key Companies Market Share (%), 2021

Key Company Profiles

• GE Healthcare
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Siemens Healthineers
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Philips Healthcare
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Curium Pharma
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cardinal Health
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bracco Imaging
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eckert & Ziegler
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lantheus Medical Imaging
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Jubilant Life Sciences
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Nordion Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• IBA Molecular
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Advanced Accelerator Applications (AAA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Progenics Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Norgine B.V.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• FUJIFILM Holdings Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer Healthcare
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Theragnostics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• RadioMedix Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ion Beam Applications S.A. (IBA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments